• Issue
    Volume 55, Issue 1
    1-149
    January 2022

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 1-3
  • First Published: 14 December 2021

A MESSAGE FROM THE EDITORS

Free Access

A Message from the Editors

  • Pages: 4-5
  • First Published: 14 December 2021

EDITORS' DECLARATIONS OF INTEREST

Free Access

AP&T: EDITORS’ DECLARATIONS OF INTEREST

  • Pages: 6-7
  • First Published: 14 December 2021

META-ANALYSIS

Free to Read

Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B

  • Pages: 8-25
  • First Published: 01 December 2021

Description unavailable

Sub-group Meta-regression analysis of HCC: (1) There was non-significant higher occurrence of HCC in patients with treatment induced HBsAg loss compared to spontaneous HBsAg loss (0.78% vs 0.35%). (2) Male gender, cirrhosis and family history of HCC were independent risk factors for HCC development after HBsAg loss. Secondary Outcomes: (1) HBsAg loss was associated with a non-significant 49% reduction in relative risk of cirrhosis (RR = 0.51; 95% CI = 0.17-1.56). (2) HBsAg loss was associated with a non-significant 37% reduction in relative risk of hepatic decompensation events (RR = 0.63; 95% CI = 0.30-1.30). (3) HBsAg loss was associated with a non-significant ~4 fold increase in risk of overall mortality (RR = 3.94; 95% CI = 0.49-31). (4) HBsAg loss was associated with a non-significant 9% reduction in relative risk of liver-related mortality (RR = 0.91; 95% CI = 0.32-2.64).

SYSTEMATIC REVIEW

Free to Read

Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease

  • Pages: 26-48
  • First Published: 09 November 2021
Description unavailable

In a systematic review of studies investigating associations between the gut microbiota and medical treatments for inflammatory bowel disease, increased alpha diversity and relative abundance of Faecalibacterium prausnitzii were markers of favourable outcomes, while increased relative abundance of Escherichia/Shigella was a consistent marker of unabated inflammation and treatment non-response.

REVIEW ARTICLE

Free to Read

Review article: insights into the bile acid-gut microbiota axis in intestinal failure-associated liver disease—redefining the treatment approach

  • Pages: 49-63
  • First Published: 29 October 2021
Description unavailable

Gut microbiota and bile acids participate in each other’s normal physiology. In intestinal failure, gut microbial dysbiosis and bile acid dysmetabolism occur; they may collaboratively induce liver disease via promoting gut barrier dysfunction and liver immune and metabolic aberration. A multitarget therapy aiming at gut microbiota and bile acids may provide optimal clinical benefits.

LONG-TERM NATURAL HISTORY OF CROHN'S DISEASE

Free to Read

The clinical course of Crohn’s disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017

  • Pages: 73-82
  • First Published: 20 September 2021
Description unavailable

Long-term prognosis of patients with Crohn's disease diagnosed 1962-1987 in a population-based Danish inception cohort.

RE-COMPENSATION IN HEPATITIS B

Free to Read

Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy

  • Pages: 83-96
  • First Published: 18 October 2021
Description unavailable

The new model consisting of six factors was established to predict re-compensation of patients with HBV-related decompensated cirrhosis. It stratified the survival and re-compensation well.

HCC RISK IN HCV PLUS FATTY LIVER

Free to Read

Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver

  • Pages: 97-107
  • First Published: 24 November 2021
Description unavailable

Concurrent fatty liver was associated with a significantly higher risk for HCC and all-cause mortality.

INVITED EDITORIALS

Free Access

Editorial: delving into the natural history of Crohn’s disease and the impact of medical therapy

  • Pages: 108-109
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Burisch et al papers. To view these articles, visit https://doi.org/10.1111/apt.16615 and https://doi.org/10.1111/apt.16680

Free Access

Editorial: rumination—more frequent than previously thought

  • Pages: 112-113
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zand Irani et al papers. To view these articles, visit https://doi.org/10.1111/apt.16630 and https://doi.org/10.1111/apt.16682

Free Access

Editorial: rumination—more frequent than previously thought. Authors’ reply

  • Pages: 114-115
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zand Irani et al papers. To view these articles, visit https://doi.org/10.1111/apt.16630 and https://doi.org/10.1111/apt.16660

Free Access

Editorial: twenty minutes of moderate-to-vigorous physical activity a day keeps the NAFLD away

  • Pages: 116-117
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Tsunoda et al papers. To view these articles, visit https://doi.org/10.1111/apt.16631 and https://doi.org/10.1111/apt.16688

Free Access

Editorial: the three tenors in HBV – TDF, TAF and now TMF

  • Pages: 120
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Liu et al papers. To view these articles, visit https://doi.org/10.1111/apt.16611 and https://doi.org/10.1111/apt.16692

Free Access

Editorial: the three tenors in HBV—TDF, TAF and now TMF. Authors' reply

  • Pages: 121
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Liu et al papers. To view these articles, visit https://doi.org/10.1111/apt.16611 and https://doi.org/10.1111/apt.16668

Free Access

Editorial: targeting liver biopsy in NAFLD – the need to expand non-invasive tools

  • Pages: 126-127
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Kim et al papers. To view these articles, visit https://doi.org/10.1111/apt.16674 and https://doi.org/10.1111/apt.16711

Free Access

Editorial: don’t forget basic performance measures in the endoscopic assessment of ulcerative colitis

  • Pages: 129-130
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Feagan et al papers. To view these articles, visit https://doi.org/10.1111/apt.16626

Free Access

Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients

  • Pages: 131-132
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Rubin et al papers. To view these articles, visit https://doi.org/10.1111/apt.16619

Free Access

Editorial: sporadic early-onset colorectal cancer—appreciating aetiologic complexity

  • Pages: 133-134
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Vuik et al papers. To view these articles, visit https://doi.org/10.1111/apt.16638

Free Access

Editorial: hepatocellular carcinoma risk prediction models following DAA-mediated SVR—more evidence needed

  • Pages: 135-136
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Tahata et al papers. To view these articles, visit https://doi.org/10.1111/apt.16632

Free Access

Editorial: can experimental biomarkers be useful for predicting HCC occurrence after sustained viral response in clinical settings?

  • Pages: 137-138
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Moyjin et al papers. To view these articles, visit https://doi.org/10.1111/apt.16691

LETTER TO THE EDITORS

Free Access

Letter: proton pump inhibitors and risk of myocardial infarction

  • Pages: 139-140
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Nolde et al papers. To view these articles, visit https://doi.org/10.1111/apt.16565 and https://doi.org/10.1111/apt.16684

Free Access

Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum

  • Pages: 143-144
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zheng et al papers. To view these articles, visit https://doi.org/10.1111/apt.16595 and https://doi.org/10.1111/apt.16698

Free Access

Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum. Authors' reply

  • Pages: 145-146
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zheng et al papers. To view these articles, visit https://doi.org/10.1111/apt.16595 and https://doi.org/10.1111/apt.16678

Free Access

Letter: hepatic steatosis in chronic hepatitis B—viral, metabolic or treatment-related?

  • Pages: 147-148
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zheng et al papers. To view these articles, visit https://doi.org/10.1111/apt.16595 and https://doi.org/10.1111/apt.16715

Free Access

Letter: hepatic steatosis in chronic hepatitis B—viral, metabolic or treatment-related? Authors' reply

  • Pages: 149
  • First Published: 14 December 2021
LINKED CONTENT

This article is linked to Zheng et al papers. To view these articles, visit https://doi.org/10.1111/apt.16595 and https://doi.org/10.1111/apt.16687